AtriCure, Inc.

What they do

AtriCure develops and sells cardiac ablation and left atrial appendage management products used in open-heart and minimally invasive procedures, as well as cryoablation probes for nerve block pain relief. It sells directly in the U.S., Germany, France, the UK, Benelux, Australia, and Canada, and through distributors elsewhere. Revenue is primarily from products it currently sells or is developing.

Revenue drivers

• Pain management (cryoICE probes) — Products like cryoSPHERE MAX and cryoXT are used to freeze nerves for post-operative pain relief; strong growth driver, with cryoSPHERE MAX cited as a key growth contributor.
• Open ablation (EnCompass clamp) — The EnCompass clamp for surgical ablation contributed to U.S. growth and is part of the open ablation franchise, which is expanding with recent product innovation.
• Appendage management (AtriClip devices) — AtriClip FLEX-Mini and PRO-Mini devices are used for LAA exclusion; these products are key contributors to U.S. and international growth, with PRO-Mini launched in the U.S. in late 2025.
• International markets — Direct sales in select European countries, Australia, and Canada, plus distributor sales elsewhere; international revenue was $28.0 million in Q2 2026, up 9.6% year-over-year.

Recent performance

In Q2 2026, worldwide revenue was $153.6 million, up 12.8% year-over-year, with U.S. revenue of $125.6 million (+13.6%). The company reported net income of $9.0 million and adjusted EBITDA of $27.3 million, versus a net loss of $6.2 million in Q2 2025. Gross margin improved to 77.2%, up 269 basis points. For the first half of 2026, revenue was $294.9 million, up 13.5% year-over-year. Full-year 2025 revenue was $534.5 million, up 14.9% from 2024.

Strategy

AtriCure's strategy focuses on product innovation, clinical science, and physician education. Recent launches include the cryoSPHERE MAX probe and AtriClip PRO-Mini, with CE mark approval in Europe for the FLEX-Mini and PRO-Mini in April 2026. The company is advancing its dual energy platform combining PFA and Advanced RFA, with first-in-human treatments in late 2025 and a clinical trial expected. Key trials include LeAAPS (enrolled 6,573 patients) and BoxX-NoAF (enrolling up to 960 subjects), aimed at expanding indications. They are investing in training programs including virtual proctoring and peer-to-peer reviews.

Risks

• Market adoption risk — Failure to achieve widespread market acceptance of products, especially new launches like the dual energy platform, could hurt operating results.
• Competition — New entrants are developing competing products and procedures, which could lead to market share loss, pricing pressure, and margin erosion.
• Clinical trial outcomes — Negative or insufficient clinical data from LeAAPS, BoxX-NoAF, or other trials could slow adoption or fail to meet regulatory requirements.
• Reimbursement changes — Adverse changes in government and private payor coverage and reimbursement policies for surgical procedures could reduce demand for AtriCure products.

Outlook

Management projects full-year 2026 revenue of approximately $602 million to $610 million and adjusted EBITDA of $85 million to $89 million. They expect GAAP net income per share of $0.05 to $0.13 and adjusted EPS of $0.24 to $0.32. Continued positive cash generation is expected for 2026.